Treatment with omalizumab normalizes the number of myeloid dendritic cells during the grass pollen season.

[1]  N. Teig,et al.  Age‐Related Changes in Human Blood Dendritic Cell Subpopulations , 2002, Scandinavian journal of immunology.

[2]  K. Bergmann,et al.  Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. , 2002, The Journal of allergy and clinical immunology.

[3]  S. Holgate,et al.  Anti‐IgE treatment: an update , 2001, Allergy.

[4]  V. Soumelis,et al.  Dendritic cell lineage, plasticity and cross-regulation , 2001, Nature Immunology.

[5]  T. Chang.  The pharmacological basis of anti-IgE therapy , 2000, Nature Biotechnology.

[6]  T. Bieber,et al.  The high-affinity IgE receptor (FcεRI) blocks apoptosis in normal human monocytes , 2000 .

[7]  C. Heusser,et al.  Therapeutic potential of anti-IgE antibodies. , 1997, Current opinion in immunology.

[8]  R. Pawankar,et al.  Nasal mast cells in perennial allergic rhinitics exhibit increased expression of the Fc epsilonRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells. , 1997, The Journal of clinical investigation.

[9]  C. Bertrand,et al.  Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a non-anaphylactogenic anti-IgE antibody , 1996, The Journal of experimental medicine.

[10]  F. Sallusto,et al.  Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha , 1994, The Journal of experimental medicine.